// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























2342 Abstracts

Evaluation of deep learning techniques (DL) in RNA sequencing data for the prediction of response to immune checkpoint inhibitors in patients with metastatic renal cell cancer m(RCC).

Sandra Alonso Paz - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Nivolumab

Correlating HLA variants and the emergence of immune-related adverse events (irAEs) from ipilimumab/nivolumab (I/N) in patients (pts) treated on CheckMate 214.

Martin H Voss - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Nivolumab

A phase II study to evaluate the safety, pharmacodynamics and efficacy of entinostat in combination with nivolumab plus ipilimumab in patients with renal cell carcinoma previously treated with nivolumab plus ipilimumab or nivolumab alone.

Roberto Pili - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Renal cell carcinoma

Nivolumab

Phase II trial of intermittent therapy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with front-line ipilimumab and nivolumab (Ipi/Nivo).

Laeth George - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Nivolumab

Impact of number of treatment lines following first-line (1L) immuno-oncology (IO) combination on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).

Audreylie Lemelin - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Nivolumab

Association between time-of-day of the immune checkpoint inhibitor (ICI) infusion and disease outcomes among patients with metastatic renal cell carcinoma (mRCC).

Nazli Dizman - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Nivolumab

Impact of sarcomatoid features on treatment outcomes in metastatic clear cell renal cell carcinoma treated with first-line immunotherapy combinations.

Kelly N. Fitzgerald - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Clear cell renal carcinoma

Nivolumab

Assessment of surgical complications in patients with metastatic clear cell renal cell carcinoma (mccRCC) receiving perioperative cabozantinib and nivolumab on Cyto-KIK clinical trial.

Karie Runcie - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Clear cell renal carcinoma

Nivolumab

Examination of resistance to nivolumab monotherapy through single-cell analysis of tumors from patients enrolled in the HCRN GU16-260 study of nivolumab monotherapy.

David A. Braun - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Nivolumab

Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma.

Nirmish Singla - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Clear cell renal carcinoma

Nivolumab

A platform for high-resolution immune liquid biopsy analysis to predict response in patients with renal cell carcinoma treated with nivolumab or cabozantinib: Preliminary data from I-RENE trial (Meet-URO 8 study).

Elena Verzoni - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Renal cell carcinoma

Nivolumab

Evaluation of PBRM1, PD-L1, CD31, and CD4/CD8 ratio as a predictive signature of response to VEGFR-TKI–based therapy in patients with metastatic renal cell carcinoma (mRCC) with IMDC intermediate prognosis: Results from the APAChE-I Study.

Chiara Ciccarese - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Nivolumab

Nivoswitch trial: Predictive value of PD-L1 in plasma and extracellular vesicles.

JAdzia Sonnleithner - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Nivolumab

Baseline circulating soluble factors as predictors of immune-related adverse events (irAEs) in patients (pts) with metastatic clear cell renal carcinoma (mRCC) treated with nivolumab: A translational NIVOREN GETUG-AFU 26 study.

Lucia Carril-Ajuria - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Clear cell renal carcinoma

Nivolumab

Long-term survivorship rates among patients with previously treated advanced renal cell carcinoma receiving nivolumab: Analyses based on ≥ 7 years of follow-up from CheckMate 025 trial.

Saby George - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Nivolumab

CaboCombo: A prospective international non-interventional study of first-line cabozantinib plus nivolumab for the treatment of patients with advanced renal cell carcinoma.

Philippe Barthelemy - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Nivolumab

Optimal treatment by invoking biologic clusters in renal cell carcinoma (OPTIC RCC).

Yu-Wei Chen - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Renal cell carcinoma

Nivolumab

A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.

Jianbo Wang - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Renal cell carcinoma

Nivolumab

Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC.

Elshad Hasanov - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Clear cell renal carcinoma

Nivolumab

Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).

Aly-Khan A. Lalani - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Renal cell carcinoma

Nivolumab

Copyright © 2026. QuantiNova All rights reserved